Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
The Pacira Pharmaceuticals price is unchanged compared to yesterday.
Currently there is a rather positive sentiment for Pacira Pharmaceuticals with 5 Buy predictions and 0 Sell predictions.
With a target price of 30 € there is a positive potential of 42.86% for Pacira Pharmaceuticals compared to the current price of 21.0 €.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
S********** s********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | 0.000% | -7.759% | -3.604% | 7.000% | -0.926% | -37.059% | -57.624% |
| Supernus Pharmaceuticals | 0.000% | -7.240% | -3.302% | 17.143% | -4.651% | 49.635% | 95.238% |
| Corcept Therapeutics Inc. | 0.950% | 1.021% | 22.907% | 59.375% | 44.691% | 253.357% | 443.626% |
| Collegium Pharmaceutical Inc | -0.850% | -17.647% | -18.182% | -14.286% | -39.130% | 17.757% | 50.898% |
Comments
Pacira BioSciences (PCRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (PCRX) had its price target raised by Needham & Company LLC from $30.00 to $32.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat